# Recursion Pharmaceuticals Case Study

## Overview and Origin

- **Name of company**: Recursion Pharmaceuticals
- **When was the company incorporated?**: Founded in 2013.
- **Founders**: Chris Gibson, PhD, and Blake Borgeson.
- **How did the idea for the company (or project) come about?**: The idea for Recursion Pharmaceuticals came from a desire to speed up and optimize the drug discovery process. Traditional drug discovery methods are slow and expensive, often taking years and costing millions of dollars. The founders aimed to address this by integrating artificial intelligence (AI) and machine learning into biological experimentation to streamline drug discovery, starting with a focus on rare diseases.
- **How is the company funded? How much funding have they received?**: Recursion has raised over $450 million in multiple funding rounds. They are backed by investors such as Baillie Gifford, Lux Capital, and SoftBank&#8203;:contentReference[oaicite:0]{index=0}&#8203;:contentReference[oaicite:1]{index=1}.

## Business Activities

- **What specific problem is the company or project trying to solve?**: Recursion addresses inefficiencies in the drug discovery process. Traditional methods are slow, costly, and come with a high failure rate. The company seeks to speed up this process by using AI to analyze massive datasets and identify potential drug candidates faster, particularly for rare diseases and fibrotic conditions.
- **Who is the company's intended customer? Is there any information about the market size of this set of customers?**: Recursion’s intended customers include pharmaceutical companies, healthcare providers, and research institutions. The global AI-driven drug discovery market was valued at over $1.1 billion in 2022 and is expected to grow significantly&#8203;:contentReference[oaicite:2]{index=2}&#8203;:contentReference[oaicite:3]{index=3}.
- **What solution does this company offer that their competitors do not or cannot offer?**: Recursion offers a unique combination of machine learning, automation, and biological experimentation. Their platform allows for high-throughput screening of compounds, drastically reducing the time it takes to identify promising drug candidates. This ability to integrate AI directly with biology sets them apart from competitors&#8203;:contentReference[oaicite:4]{index=4}&#8203;:contentReference[oaicite:5]{index=5}.
- **Which technologies are they currently using, and how are they implementing them?**: Recursion uses AI-driven high-throughput screening, automation, and machine learning algorithms to analyze biological data. Their platform integrates predictive modeling and machine learning to evaluate the behavior of drug candidates faster and more accurately than traditional methods&#8203;:contentReference[oaicite:6]{index=6}.

## Landscape

- **What field is the company in?**: Recursion operates in the field of AI-driven biopharmaceuticals and drug discovery, focusing on accelerating the development of treatments for rare diseases and fibrotic conditions&#8203;:contentReference[oaicite:7]{index=7}.
- **What have been the major trends and innovations of this field over the last 5–10 years?**:
    - The use of AI and machine learning to process large datasets and identify potential drug candidates quickly.
    - High-throughput screening and automation to conduct biological experiments at scale.
    - Predictive modeling to simulate how compounds behave in biological systems.
    - Integration of AI with laboratory processes to accelerate drug discovery and development&#8203;:contentReference[oaicite:8]{index=8}&#8203;:contentReference[oaicite:9]{index=9}.
- **What are the other major companies in this field?**:
    - **Insilico Medicine**: AI-powered drug discovery focused on aging and cancer research&#8203;:contentReference[oaicite:10]{index=10}&#8203;:contentReference[oaicite:11]{index=11}.
    - **Atomwise**: Specializes in virtual molecular screening using AI&#8203;:contentReference[oaicite:12]{index=12}.
    - **Exscientia**: Uses AI to design small molecules for precision medicine&#8203;:contentReference[oaicite:13]{index=13}&#8203;:contentReference[oaicite:14]{index=14}.
    - **Iktos**: Focuses on AI for small molecule drug discovery&#8203;:contentReference[oaicite:15]{index=15}.

## Results

- **What has been the business impact of this company so far?**: Recursion has made substantial progress in advancing multiple drug candidates into clinical trials, particularly in rare diseases. Their partnerships with major pharmaceutical companies like Bayer and Takeda highlight the success of their AI platform. They have significantly reduced drug discovery timelines compared to traditional methods&#8203;:contentReference[oaicite:16]{index=16}&#8203;:contentReference[oaicite:17]{index=17}.
- **What are some of the core metrics that companies in this field use to measure success? How is your company performing based on these metrics?**: Metrics include:
    - **Time to discovery**: Recursion has successfully reduced drug discovery timelines through their high-throughput AI platform.
    - **Number of clinical trials initiated**: The company has moved several drug candidates to preclinical and clinical trials.
    - **Partnerships and collaborations**: Recursion has established strong partnerships with companies such as Bayer and Takeda, further proving the effectiveness of their platform&#8203;:contentReference[oaicite:18]{index=18}&#8203;:contentReference[oaicite:19]{index=19}.
- **How is your company performing relative to competitors in the same field?**: Recursion's large-scale integration of AI, automation, and biology gives them a unique competitive advantage. Their focus on rare diseases and drug repurposing distinguishes them from competitors such as Insilico Medicine and Exscientia&#8203;:contentReference[oaicite:20]{index=20}&#8203;:contentReference[oaicite:21]{index=21}.

## Recommendations

- **If you were to advise the company, what products or services would you suggest they offer?**: I would recommend Recursion explore expanding their AI platform into the field of personalized medicine, offering tailored treatment solutions based on genetic profiles. They could also enter the gene therapy space by applying AI to optimize gene editing technologies like CRISPR.
- **Why do you think that offering this product or service would benefit the company?**: Expanding into personalized medicine would allow Recursion to tap into a growing market. Offering gene therapy solutions could also diversify their portfolio and open up new revenue streams through partnerships and collaborations&#8203;:contentReference[oaicite:22]{index=22}.
- **What technologies would this additional product or service utilize?**: Technologies such as next-generation sequencing, AI-powered gene editing (e.g., CRISPR), and advanced data analysis for personalized treatment plans.
- **Why are these technologies appropriate for your solution?**: AI's ability to rapidly analyze large datasets and generate tailored solutions makes it ideal for personalized medicine and gene therapy, where precision is critical&#8203;:contentReference[oaicite:23]{index=23}&#8203;:contentReference[oaicite:24]{index=24}.

---

## Sources

- [GEN News - AI in Drug Discovery](https://www.genengnews.com/)
- [Nanalyze - Recursion Pharmaceuticals Overview](https://www.nanalyze.com/)
